太阳成集团tyc33455cc官网附属同济医院肝胆外科中心主任，美国匹兹堡大学医学中心访问学者，主任医师，医学博士，博士研究生导师，博士后导师。
兼任中国医药教育协会肝胆智能装备发展促进分会主任委员，上海吴孟超医学科技基金会肝胆腔镜外科医师联盟理事长，北京世纪慈善基金会肝胆腔镜外科医师志愿者公益基金理事长，首届国际肝胆胰协会中国转移性肝癌专业委员会秘书长，中国医药教育协会医疗装备发展促进工作委员会常委，首届国际肝胆胰协会中国腹腔镜肝脏切除发展与推广委员会委员，中国研究型医院学会智能医学专业委员会委员，上海市政府采购评审专家。
Director of Hepatobiliary Surgery Center, Tongji Hospital, Tongji University; Visiting Scholar, University of Pittsburgh Medical Center; Chief Physician, M.D., Supervisor of doctoral students, Postdoctoral Supervisor.
Director of Hepatobiliary Intelligent Equipment Development and Promotion Branch of China Medical Education Association, Chairman of Hepatobiliary Luminal Surgery Physicians Union of Shanghai Wu Mengchao Medical Science and Technology Foundation, Chairman of Hepatobiliary Luminal Surgery Physicians Volunteer Public Welfare Fund of Beijing Century Charitable Foundation, Secretary General of Metastatic Liver Cancer Specialized Committee of the First International Hepatobiliary and Pancreatic Association of China, Member of the Standing Committee of Medical Equipment Development and Promotion of the China Medical Education Association, Member of the First Member of China Laparoscopic Liver Resection Development and Promotion Committee of International Hepatobiliary and Pancreatic Association, Member of Intelligent Medicine Specialized Committee of China Society of Research Hospitals, Expert of Shanghai Municipal Government Purchasing Assessment.
累计接诊肝胆外科患者约30000人次，开展肝胆外科手术约5000例。累计获国家重点研发计划智能机器人专项子课题、国家自然科学基金面上项目、上海市科委重点项目等各类纵向基金资助500余万元；发表论文30余篇，其中在《Clinical and Translational Medicine》、《International Journal of Biological Sciences》、《American Journal of Physiology-Gastrointestinal and Liver Physiology》、《Chemico-Biological Interactions》、《Phytomedicine》等高质量SCI杂志上发表论文20余篇；获国家专利授权16项，其中发明专利授权5项；以第一完成人获得省部级科技创新应用研究奖二等奖1项，省部级科技创新基础研究奖1项，省部级科技进步基础研究奖1项，军队医疗成果奖3项。2011年入选上海市卫生系统新优青。
近五年主持或参加的国家自然科学基金项目/课题如下：
(1)国家自然科学基金委员会，面上项目，82170412，血管内皮细胞RNA编辑酶ADAR1减少导致糖尿病伤口愈合障碍的机制研究，2022-01-01至2025-12-31，55万元，在研，主持
(2)国家自然科学基金委员会，面上项目，81970565，IRF-1-Rab27a轴调控的外泌体促进部分肝移植术后肝再生：miR-122/CXCR4双信号远程传递，2020-01-01至2023-12-31，55万元，结题，分中心负责人
代表性论著和专利如下：
(1) Xiaoye Qu； Yankai Wen； Junzhe Jiao； Jie Zhao； Xuehua Sun： Fang Wang： Yueqiu Gao； WeifengTan： Qiang Xia； Hailong Wu； Xiaoni Kong ； PARK7 deficiency inhibits fatty acid β-oxidation via PTEN to delay liver regeneration after hepatectomy， Clinical and Translational Medicine，2022, 12(9): e1061.
(2) Yun Pan； Wei-feng Tan； Mu-qing Yang； Ji-yu Li； Davide A. Geller ； The therapeuticpotential of exosomes derived from different cell sourcesin liver disease， American Journal of Physiology-Gastrointestinaland Liver Physiology， 2022， 322(4)：G397-G404.
(3) Li， Xiang； Yu， Chang； Luo， Yichun； Lin， Jiacheng； Wang， Fang； Sun， Xuehua； Gao， Yueqiu；Tan， Weifeng； Xia， Qiang； lang； Kong，Xiaoni； Aldolase A Enhances Intrahepatic Cholangiocarcinoma Proliferation and Invasion through Promoting Glycolysis， International Journal of Biolical Sciences，2021，17(7)：1782-1794.
(4) Hai Zhang； Qingshan Chen； Arik Dahan； Jiyang Xue； Liwen Wei； Weifeng Tan； Guoqing ZhangTranscriptomic analyses reveal the molecular mechanisms of schisandrin B alleviates CC14-inducedliver fibrosis in rats by RNA-sequencing，，Chemico-Biological1 Interactions，2019，309：108675.
(5) Weifeng Tan： Zhiquan Qiu； Yong Yu； Rongzheng Ran； Bing Yi； Wanyee Lau； Chen Liu； YingheQiu； Feiling Feng； Jinghan Wang； Peining Yan； Baihe Zhang； Mengchao Wu； Xiangji Luo； XiaoqingJiang ； Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation， Acta Pharmacologica Sinica，2010，31(12)：1643-1648.
The total number of patients of hepatobiliary surgery is about 30,000, and about 5,000 cases of hepatobiliary surgery have been carried out. He has been granted more than 5 million RMB from various vertical funds, such as the sub-projects of the National Key Research and Development Program for Intelligent Robotics, the top-level project of the National Natural Science Foundation of China, and the key project of Shanghai Municipal Science and Technology Commission, etc. He has published more than 30 papers, among which more than 30 papers have been published in the Clinical and Translational Medicine, the International Journal of Clinical and Translational Medicine, International Journal of Biological Sciences, American Journal of Physiology-Gastrointestinal and Liver Physiology, Chemico-Biological Interactions, Phytomedicine. Phytomedicine” and other high-quality SCI journals, he has published more than 20 papers; he has been authorized 16 national patents, including 5 invention patents; he has been awarded the second prize of Provincial and Ministerial Scientific and Technological Innovation and Applied Research Award, Provincial and Ministerial Scientific and Technological Innovation and Basic Research Award, Provincial and Ministerial Scientific and Technological Progress and Basic Research Award, and the Army Medical Achievement Award, and he was selected as the new outstanding youth of Shanghai Health System in 2011.
The following NSFC programs/projects have been chaired or participated in the last five years:
(1) National Natural Science Foundation of China, Faceted Project, 82170412, Mechanism study on the reduction of vascular endothelial cell RNA editing enzyme ADAR1 leading to impaired diabetic wound healing, 2022-01-01 to 2025-12-31, 550,000 RMB, under research, presided over
(2) National Natural Science Foundation of China, Top Project, 81970565, IRF-1-Rab27a axis-regulated exosomes promote liver regeneration after partial liver transplantation: miR-122/CXCR4 dual signaling teleportation, 2020-01-01 to 2023-12-31, 550,000 Yuan, under research, participation
Representative publications are listed below:
(1) Xiaoye Qu； Yankai Wen； Junzhe Jiao； Jie Zhao； Xuehua Sun： Fang Wang： Yueqiu Gao； WeifengTan： Qiang Xia； Hailong Wu； Xiaoni Kong ； PARK7 deficiency inhibits fatty acid β-oxidation via PTEN to delay liver regeneration after hepatectomy， Clinical and Translational Medicine，2022, 12(9): e1061.
(2) Yun Pan； Wei-feng Tan； Mu-qing Yang； Ji-yu Li； Davide A. Geller ； The therapeuticpotential of exosomes derived from different cell sourcesin liver disease， American Journal ofPhysiology-Gastrointestinaland Liver Physiology， 2022， 322(4)：G397-G404.
(3) Li， Xiang； Yu， Chang； Luo， Yichun； Lin， Jiacheng； Wang， Fang； Sun， Xuehua； Gao， Yueqiu；Tan， Weifeng； Xia， Qiang； lang； Kong，Xiaoni； Aldolase A Enhances Intrahepatic Cholangiocarcinoma Proliferation and Invasion through Promoting Glycolysis， International Journal of Biolical Sciences，2021，17(7)：1782-1794.
(4) Hai Zhang； Qingshan Chen； Arik Dahan； Jiyang Xue； Liwen Wei； Weifeng Tan； Guoqing ZhangTranscriptomic analyses reveal the molecular mechanisms of schisandrin B alleviates CC14-inducedliver fibrosis in rats by RNA-sequencing，，Chemico-Biological1 Interactions，2019，309：108675.
(5) Weifeng Tan： Zhiquan Qiu； Yong Yu； Rongzheng Ran； Bing Yi； Wanyee Lau； Chen Liu； YingheQiu； Feiling Feng； Jinghan Wang； Peining Yan； Baihe Zhang； Mengchao Wu； Xiangji Luo； XiaoqingJiang ； Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation， Acta Pharmacologica Sinica，2010，31(12)：1643-1648.
